TL;DR
This study investigates the relationship between cholesterol levels and subclinical atherosclerosis in HIV-positive patients, finding that non-HDL cholesterol and apolipoprotein B are stronger predictors than LDL cholesterol. These findings highlight the importance of targeting non-HDL cholesterol for cardiovascular risk reduction in this population.
What Problem Does This Paper Address?
Cardiovascular disease (CVD) is a significant concern for individuals living with HIV, who are exposed to multiple risk factors, including those related to HIV infection itself and the antiretroviral therapies used to manage it. While traditional cardiovascular risk factors are known, there's a need to better understand and identify specific markers that predict subclinical atherosclerosis (early signs of artery hardening) in this population. This paper aims to assess the association between various non-classical cardiovascular risk factors, including different lipid profiles, metabolic syndrome, and carotid intima-media thickness (CIMT), a marker of atherosclerosis. The goal is to identify more effective targets for prevention and treatment to reduce CVD complications in HIV-positive individuals.
Methods
The study employed a cross-sectional design, analyzing data from 232 HIV-positive adults who were part of the ANRS CO3 Aquitaine Cohort. Key measurements included:
- Carotid Intima-Media Thickness (CIMT): Measured using high-resolution B-mode ultrasonography on the far wall of the left common carotid artery.
- Lipid Parameters: Including total cholesterol (TC), non-HDL cholesterol (non-HDL-C), LDL cholesterol (LDL-C), triglycerides (TG), HDL cholesterol (HDL-C), apolipoprotein B (apoB), and apolipoprotein A1 (apoA1). LDL-C was calculated using the Friedwald's formula, with a note on its limitations for patients with high TG levels.
- Metabolic Syndrome (MS) and Lipid Triad (LT): Defined using established criteria (NCEP-ATP III and IDF for MS, and a specific combination of lipid disorders for LT).
- Inflammation and Oxidative Stress Markers: Including hs-CRP, albumin, prealbumin, AOPP, MDA, AGEs, MDA-LDL Ab, and TAC.
- Immuno-virological Parameters: CD4+ cell count and HIV-1 viral load.
Statistical analyses included Student's t-tests, ANOVA, Spearman correlation, and multiple linear regression to adjust for age, gender, and tobacco consumption.
Datasets
The study utilized data from the ANRS CO3 Aquitaine Cohort, specifically a subgroup of 232 HIV-positive patients. This cohort was established to study atherosclerosis progression in HIV-infected individuals.
Key Insights and Ideas
- Non-HDL Cholesterol as a Superior Predictor: The study strongly suggests that non-HDL cholesterol is a more potent predictor of subclinical atherosclerosis in HIV-positive patients than LDL cholesterol, a finding that has implications for current lipid management guidelines.
- Apolipoprotein B's Role: Similar to non-HDL-C, apolipoprotein B also showed a significant association with CIMT, reinforcing its importance in assessing cardiovascular risk in this population.
- Metabolic Syndrome's Impact: The presence of metabolic syndrome, regardless of the definition used, was significantly associated with increased CIMT, highlighting the systemic impact of this cluster of metabolic abnormalities.
- Lipid Triad's Limited Association: Surprisingly, the lipid triad (defined by high TG, low HDL-C, and small LDL size) did not show a significant association with increased CIMT in this HIV cohort, suggesting that other mechanisms might be at play or that the specific components of the triad have varying impacts.
- Complex Dyslipidemia in HIV: The paper touches upon the complex dyslipidemia seen in HIV patients treated with c-ART, which is influenced by both the virus itself and the medications, making management a challenge.
Key Results
- Higher levels of non-HDL-C (p<0.01), apolipoprotein B (p<0.01), and TG/HDL ratio (p<0.05) were significantly associated with higher CIMT in univariate analysis.
- After adjusting for age, gender, and tobacco consumption, the association between TG/HDL molar ratio >1.5 and CIMT showed a trend toward significance (p=0.08).
- LDL-C (p=0.09) and LDL size (p=0.55) did not show a significant association with CIMT.
- Metabolic syndrome was present in 7.3% (NCEP-ATP III) and 11.2% (IDF) of patients and was significantly associated with increased CIMT (p<0.05) in both univariate and multivariate analyses.
- The study found that non-HDL-C, apoB, and TG/HDL ratio were stronger predictive factors for increased CIMT than LDL-C in univariate analysis.
Limitations and Future Work
- Cross-sectional Design: The authors acknowledge that the cross-sectional nature of the study limits the ability to establish causality and predict the progression of CIMT or cardiovascular events.
- Low Prevalence of MS: The relatively low prevalence of metabolic syndrome in this cohort might have limited the power to detect certain associations.
- Future Research: The authors suggest that further prospective studies are needed to evaluate the capacity of non-HDL-C, apoB, and TG/HDL ratio in predicting CIMT progression and cardiovascular events in larger cohorts of HIV-positive patients. They also emphasize the importance of achieving non-HDL-C targets for reducing cardiovascular complications in this population.
Summary updated